Comparison of Poor Sleep Quality in Inflammatory Bowel Disease (IBD) Patients and the General Population

Understanding how sleep quality in patients with inflammatory bowel disease (IBD) compares to that of the general population is vital for clinical management, given the significant impact that poor sleep has on disease outcomes and overall well-being. Various studies utilizing subjective questionnaires and objective measures have consistently shown that sleep disturbances are much more prevalent and severe in IBD patients compared to healthy individuals.

Prevalence of Poor Sleep Quality in IBD versus the General Population

The prevalence of poor sleep quality among IBD patients is notably higher than in the general population. For example, research involving large cohorts of IBD patients commonly reports that approximately 60% to 75% of individuals with IBD experience poor sleep quality as measured by validated tools such as the Pittsburgh Sleep Quality Index (PSQI). This contrasts sharply with general population estimates, where the prevalence tends to be substantially lower, often around 30% or less.

A cross-sectional study in Switzerland involving 1,139 IBD patients contrasted with an age-, sex-, and BMI-matched general population sample found that 61.3% of IBD patients had impaired sleep quality based on PSQI scores, compared with only 33.9% in controls. This study further noted a higher prevalence of daytime sleepiness and restless leg syndrome in the IBD group, emphasizing the broad nature of sleep disturbances affecting these patients (Caloz, 2020).

Similarly, a multicenter study in China enrolling 2,478 IBD patients reported a 60.17% prevalence of poor sleep quality, with older patients experiencing even higher rates compared to younger counterparts. The general population’s prevalence of poor sleep is considerably less, reinforcing the distinct burden of sleep impairments in IBD (Zeng, 2023).

In an Iranian cohort, 32.4% of IBD patients exhibited poor sleep quality, which was higher in those with moderate disease activity. While this percentage is slightly lower than other reports, it still exceeds typical population rates and underscores variability that can arise due to population, disease heterogeneity, and assessment methods (Mahdavi, 2019).

Moreover, a thematic analysis from an online survey of 312 adults with IBD showed that 75% of participants reported poor sleep quality, with many recognizing a bi-directional interaction between sleep and disease activity. The general population aside from specific clinical samples rarely exhibits such a strong association between sleep quality and chronic inflammatory disease, highlighting an IBD-specific vulnerability (Salwen-Deremer, 2022).

Objective Sleep Measures and Comparisons with Controls

Objective investigations using wrist actigraphy and polysomnography further corroborate that IBD patients have significantly altered sleep architectures compared to healthy individuals. Sleep fragmentation, increased sleep latency, more frequent awakenings, and decreased sleep efficiency have been commonly reported among patients with both active and inactive IBD.

For instance, actigraphy-based studies observed that IBD patients, especially those with more active disease, demonstrated longer sleep onset latency and poorer sleep efficiency compared to controls. In a study of 84 patients stratified by disease activity, those with moderate-to-severe disease had notably worse objective sleep parameters compared to those in remission, though overall sleep disturbances were present across the spectrum (Chaemsupaphan, 2024).

Polysomnographic assessment of IBD patients in remission reported increased arousal indices and sleep fragmentation in comparison with matched healthy controls. Such findings suggest that even when clinical inflammation appears quiescent, intrinsic sleep disruptions persist in the IBD population, differentiating them from typical sleep patterns in the general population (Beilman, 2020).

Factors Contributing to Differences in Sleep Quality

Several reasons have been proposed to explain why sleep quality is worse in IBD patients than in the general population:

• Disease Activity and Subclinical Inflammation: Active inflammation exacerbates sleep disturbances, likely through cytokine-mediated effects on the central nervous system and circadian rhythms. Moreover, even histologically active but clinically quiescent disease correlates with poor sleep, indicating that subclinical inflammatory processes contribute to sleep impairment (Ali, 2013).

• Psychological Comorbidities: Anxiety and depression are more prevalent in IBD patients and are robustly associated with poor sleep quality. Such psychological burdens are less prevalent in the general population and mediate the severity of sleep disturbances in IBD (Yu, 2023).

• Medication Effects: Certain drugs, including corticosteroids and opioids, commonly used in IBD management, are linked with worsened sleep quality, an influence that is minimal or absent in the general population (Barnes, 2023).

• Behavioral and Cognitive Factors: Patients with IBD may engage in dysfunctional sleep habits, such as daytime napping and lying awake in bed due to pain or worry, which are less common in healthy populations and exacerbate poor sleep (Salwen-Deremer, 2022).

• Inflammation-Related Pathways: Large-scale proteomic studies indicate shared inflammatory pathways between sleep disturbances and IBD pathophysiology that do not typically affect individuals without IBD, implying a disease-specific mechanism (Le, 2025).

Impact of Poor Sleep Relative to the General Population

Poor sleep quality in IBD patients is linked to more severe fatigue, greater symptom burden, and worse health-related quality of life than what is commonly observed in the general population. This enhanced impact likely arises from the compounding effects of chronic inflammation, gastrointestinal symptoms, and psychological distress.

Clinical studies have demonstrated that sleep disturbances in IBD predict higher rates of disease flares, hospitalizations, and surgery, outcomes not generally seen in the broader population due to sleep disturbances alone. These adverse consequences highlight the prognostic importance of sleep quality in the IBD setting (Xu, 2025).

Summary

In conclusion, poor sleep quality is markedly more prevalent and severe among persons with inflammatory bowel disease compared to the general population. Both subjective and objective studies establish that a majority (often exceeding 60%) of IBD patients experience significant sleep disturbances, whereas much lower proportions of healthy individuals are similarly affected. These disparities stem from disease-specific inflammatory processes, psychological comorbidities, medication effects, and maladaptive sleep behaviors. Given the profound influence on disease activity and patient quality of life, poor sleep in IBD represents a distinct clinical concern that merits routine assessment and tailored management, contrasting with approaches suitable for the general population (Caloz, 2020).

Please let me know if you would like further elaboration on specific mechanisms underlying this difference, details about measurement methods, or intervention strategies targeting poor sleep in IBD.